Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
Triple-Negative Breast Carcinoma
Explore 428 assets in Triple-Negative Breast Carcinoma →Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
other_biological
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07300475CT.gov Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa (this asset) | Washington University School of Medicine | P1 | C · 37 |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
| Adriamycin | Yuan Yuan | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Pembrolizumab | M.D. Anderson Cancer Center | P3 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Head And Neck Squamous Cell Carcinoma | — | P1 | CC · 41 |
| Non-Small Cell Lung Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/humanized-immunoglobulin-g1-kappa-anti-human-cd8-fused-at-the-c-terminus-of-one-heavy-chain-via-peptide-linker-sup449sup-sggggsggggsggggssup464sup-to-a-variant-of-human-interleukin-2-glycoform-alfa-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →